Plandai Biotechnology announces positive results for anti-malarial plant extract

Plandai Biotechnology, Inc., a producer of highly bioavailable plant extracts for multiple industries, announced on Wednesday that its Phytofare catechin extract was effective in killing the malaria parasite in a recent study.

Phytofare was found to be effective in killing plasmodium falciparum in analytical tests developed and conducted under the supervision of Sanjeev Krishna, a scientist with the London School of Medicine. The study found that Epigallocatechin Gallate, which was isolated from the Phytofare extract, effectively killed the parasite with a lower dosage than a purified EGCG extract.

"These initial findings provide evidence corroborating previous scientific findings that ECGC catechin can kill the malaria parasite," Roger Duffield, the CEO of Plandai, said. "This study involving Phytofare is the first to show the effectiveness of using a commercial botanical extract, rather than purified extract of EGCG catechin, as an anti-malarial. We believe these results validate our decade-long research into the opportunity for using botanical extracts as a means to combat one of the world's great plagues. Dr. Krisha's clinical data indicate that Phytofare extract has a stable platform with predictable outcomes, making it a suitable candidate for further investigations."

Plandai is working on the finalization of agreements to undertake future in vitro and mouse studies at the University of Cape Town to further validate Phytofare catechin complex with a total of eight catechins, rather than the isolated EGCG.

"We now have the opportunity evaluate the extract in further studies, including inhibiting the parasite in the glucose transporter and as a potential prophylactic by destroying the sporozoites during their journey from injection into the human blood by the female mosquito to the liver," Duffield said.

After the evaluation of study results, Plandai will submit an application with the U.S. Food and Drug Administration to start Phase II human clinical trials.